The difference now, after the reverse split, is that profit takers are alive and active on the significant percentage increases. There is that resistance to plow through, and you will see people shorting the spikes along with the profit taking... Just buy these dips and deal with the ups and downs.
These women really have no options at this stage in their Chest Wall cancer progression, anything that can help to alleviate pain or to induce a complete response should be fast tracked for this population group.
You have to read exhibit 99.1 in the 8K,
"This case took a dramatic turn on November 13, 2013, when Netlist’s CEO, Chuck Hong, received a whistleblower letter postmarked from Canada"
Market cap should adjust to match the forward outlook, it should gap up and probably see some selling on the news, would be a good time to add on the dips, if DHS favors WYY again.
TSYS does have 150million debt (according to yahoo stats) whereas WYY is only 4 million or so,
Marqibo is a Liposome delivery system, perhaps SPPI wants to partner with down-trodden CLSN and their Heat-sensitive Liposome delivery of Doxorubicin, they could just partner cheap for the Chest Wall indication, as an example.
It was also discovered by Twitter follower who used Freedom of Information Act to get details of the dispute.
Go read or listen to the 3rd Q earnings call, simple enough. They guided 2 contract announcements and have only announced 1 so far... DHS was not included in the 2.
Interesting. This has all the hallmarks of becoming a great expose on 60 minutes, imagine a "Mike Wallace-like" grilling some Diablo executive, certainly worthy of the spotlight.
MST188 PIII is built to succeed, they are optimizing the trial based on the positive results that were in the prior trial that failed to meet endpoints. Younger population showed 21hours reduced crisis duration and that would easily pass FDA goals for the EPIC trial.
Baker Brothers held through the prior PDUFA and got the CRL. I think it should be approved and perhaps Baker Brothers will be vindicated, but with FDA, one never knows.
Re: Durability of Effect. The FDA and CHTP both realize that you have a hard time quantifying DOE in this patient population as they find the subjective question difficult to compartmentalize. One patient specifically told them as much...
They are prone to recalibrating the baseline from week to week as these are elderly Parkinson's patients who really can't be expected to be sharp enough to present solid data points every week. That is why they feel the short term effect should have the most importance, it is the easiest for the patients to quantify.
They have a better understanding and awareness about the process and how to best try to assess and gather the information in a clearer manner.
Shelf filing is discretionary, up to 25 million. They may not use the shelf at all, they may raise $5 million, $10 million, etc. I don't think you can say they are going to use the whole $25 million at this point.
There is no guarantee they will raise any capital, there is no guarantee they will raise $25 million, that is just the limit. Companies file S-3 shelf all the time and many go unused. They may use it to raise some cash, sure, but there are no details.
They have not announced any capital raise, don't people understand shelf filings? They aren't dilution announcements.
Every single company who ever thinks about needing capital somewhere along the way needs to file an S-3 shelf filing. Many companies do it routinely as they have limited life-spans, they need to be renewed every few years. Often, the company filing will NEVER need to tap funds from a shelf filing, they go unused. Pretty much every development level biotech has a shelf filing to enable them the ability to raise when necessary.
Shelf filing with the SEC is not a notice of dilution, though they can lead to a dilution down the road when the share price is more optimal... If WYY does have another contract announcement coming soon, they might want to wait to think about raising capital in this shelf, announce good news and let the market realize the potential so you can raise at a higher price because the demand for shares will be greater.
Every small cap company files a shelf, many are never used, some are used a little, very few use up the entire shelf in one sweeping dilution. They tap the filing little by little depending on needs.